From: Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
Best Response – D100
# Pt
%
CR
1
7% (1/14)
nCR
10
72% (10/14)
VGPR
0
PR
3
21% (3/14)
SD
PD
Total
14
100%